Murata is seeking startups to trial its innovative cell fractionation filter, CELLNETTA, to identify key challenges this product can solve.
Seeking 4-6 startups to participate in the ILP Beijing Virtual Symposium on November 5, 2020.
How can P&G enable consumers to do radically more with radically less water and energy use? How can we make invisible use of water & energy visible, right at the point of use? How might we particularly address the triangle of tension that exists between improving sanitization, reducing water & energy, whilst keeping the feeling of abundance of using water?. From incremental evolution to product innovation, easy-retrofit water-infrastructure changes (taps, faucets, showerheads, etc.) and water appliances that aim at both reducing (hot) water and re-using/purifying/enriching (hot) water, we want to partner!
2019 IoT - Startup Lightning Talks
P&G is looking for startups to build new, cost-effective, data-based pipelines to reach the store owners and expand P&G exposure to them, and therefore P&G’s sales and assortment.
P&G is looking for a number of solutions to improve human-robot collaboration and safety. There are three distinct use cases: highly reliable object detection, deterministic localization for mobile robots, and highly reliable recognition of humans.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Rana el Kaliouby, CEO & Cofounder, Affectiva